GlassScriptPhysician profile
Michael Conrad Hunter
NPI 1376939827
$32,705.47
in general payments reported to CMS, 2019-2025
7 companies · $32K in 2025
The $32K reported for 2025 was more than what 95% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $290 · 2020: $28.90 · 2024: $170 · 2025: $32K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $27K · Consulting Fee: $3,438 · Travel and Lodging: $2,026 · Food and Beverage: $385.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $26,537.50 |
| Consulting Fee | $3,437.50 |
| Travel and Lodging | $2,026.09 |
| Food and Beverage | $385.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $32,216.31 | 2025 | Uplizna |
| Ucb, INC. | $146.48 | 2024 | Zilbrysq, Rystiggo |
| Nevro Corp. | $140.34 | 2019 | |
| Csl Behring | $99.34 | 2019 | |
| Alexion Pharmaceuticals, INC. | $55.51 | 2019-2020 | |
| Sarepta Therapeutics, INC. | $23.97 | 2019 | |
| Argenx US, INC. | $23.52 | 2024 | Vyvgart |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Hunter listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.